Vland's Subsidiary Selected as Top 100 Shandong Innovative Private Enterprises

On August 19th, Qingdao Vland Biotech Group Co., Ltd., a subsidiary of Qingdao Vland Biotech Inc. was selected as Top 100 Innovative Private Enterprises in Shandong province which ranks No.3 in GDP among all China’s provinces, autonomous regions and municipalities.

Technological innovation is the core driving force for Vland’s development. With the philosophy of self-innovation in mind, Vland has been improving its technologies to increase product quality, optimize product mix and reduce production costs. In accordance with the semiannual report, Vland invested around USD 7.2 million in R&D in the first half year, accounting for 8.5% of the operating income and representing a relatively high level in the industry.

Vland has built 8 technology centers and 2 laboratories, and relies on 9 nation-level innovation platforms to carry out R&D work with the market as the orientation. Strong independent innovation ability and technical strength are the core competitiveness that promotes Vland’s rapid development. In the first half of 2021,

a) Vland’s R&D project "The transformation and industrialization of feed xylanase" won the third prize of the Science and Technology Award of Shandong Biological Fermentation Association;

b) Vland and its subsidiaries were selected as Top 100 Science and Technology Enterprises in China Light Industry, Leading Technological Innovation Enterprise in 2020 and the third batch of "Little Giants" enterprise announced by the Ministry of Industry and Information Technology of the People's Republic of China;

c) Vland got 12 new authorized Chinese invention patents, 1 U.S. patent, 1 European patent and 5 PCT applications. As of the end of the reporting period, Vland and its subsidiaries owned 264 authorized Chinese invention patents, 6 US authorized patents, 2 European authorized patents, 20 PCT applications and 37 new veterinary drug registration certificates (including 3 China national first-class new veterinary drugs).

 "Talents First” is always the development strategy of Vland. Through years of growth, the company has established a stable and professional talent team, which serves as the foundation for Vland’s fast development. Currently Vland has 34 Ph.Ds and 233 full-time R&D personnel (a year-on-year increase of 7.87%), including 1 in China National “Ten Thousand Talents Program”, 5 Shandong Taishan Industry Leaders, 1 in Shandong “Double Hundred Talent Plan”, 3 Qingdao Innovation and Entrepreneurship Talents, 2 Qingdao Top Talents and 1 Weifang Yuandu Industry Leader. At the same time, Vland has established good cooperative relations with universities, scientific research institutes and other enterprises.